|Application ||WB, IHC-P, IHC-F, FC, E, IP, CHIP, IH|
|Calculated MW||6614 Da|
|Purification||Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant|
|Shelf Life||18 months from date of despatch.|
|Other Names||CAMPATH-1 antigen, CDw52, Cambridge pathology 1 antigen, Epididymal secretory protein E5, Human epididymis-specific protein 5, He5, CD52, CD52, CDW52, HE5|
|Target/Specificity||Rat anti-Human CD52 antibody, clone YTH34.5 reacts with the human CD52 antigen, also known as CAMPATH-1. The CD52 antigen is a remarkably small but heavily glycosylated peptide attached to the cell surface membrane via a GPI link (Xiaet al.1991).The apparent molecular mass of the native antigen on SDS-PAGE is 25-29kDa, considerably reduced following N-glycanase treatment (Rowanet al.1998).CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.Humanised versions of CAMPATH-1 specific antibodies are currently in clinical trials for the treatment of a range of lymphoid malignancies (Deardenet al.2002;Pettittet al.2012).|
|Preservative & Stabilisers||0.09% Sodium Azide|
|Storage||Store at +4℃ or at -20 ℃.|
|Precautions||Anti-Human CD52 Antibody, clone YTH34.5 is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
1. Hale G et al. (1998) Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.Blood. 92 (12): 4581-90. 2. Salisbury JR et al. (1994) Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.J Clin Pathol. 47 (4): 313-7. 3. Rodig SJ et al. (2006) Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).Clin Cancer Res. 12 (23): 7174-9. 4. Haniffa, M. et al. (2009) Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation.J Exp Med. 206: 371-85. 5. Ratzinger, G. et al. (2003) Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.Blood. 101: 1422-9. 6. Hu, Y. et al. (2009) Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.Immunology. 128: 260-70. 7. Golay, J. et al. (2006) The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis.Haematologica. 91: 322-30. 8. Klangsinsirikul, P. et al. (2002) Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution.Blood. 99: 2586-91. 9. Piccaluga, P.P. et al. (2007) Expression of CD52 in peripheral T-cell lymphoma.Haematologica. 92: 566-7. 10. Gopcsa, L. et al. (2005) Extensive flow cytometric characterization of plasmacytoid dendritic cell leukemia cells.Eur J Haematol. 75: 346-51. 11. Chang, S.T. et al. (2007) CD52 expression in non-mycotic T- and NK/T-cell lymphomas.Leuk Lymphoma. 48: 117-21. 12. Westermann, J. et al. (2005) CD52 is not a promising immunotherapy target for most patients with multiple myeloma.Int J Hematol. 82: 248-50. 13. Reimer, P. et al. (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study.J Clin Oncol. 27: 106-13. 14. Zand, M.S. et al. (2005) A renewable source of donor cells for repetitive monitoring of T- and B-cell alloreactivity.Am J Transplant. 5: 76-86. 15. Rizzo, K. et al. (2009) Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation.Cytometry B Clin Cytom. 76: 142-9. 16. Miles, R.R. et al. (2007) Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report.Br J Haematol. 138: 506-12. 17. Bisig, B. et al. (2013) Molecular and phenotypic features are shared by CD30-positive peripheral T-cell lymphomasHaematologica 98: 1250-8.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.